210 related articles for article (PubMed ID: 34210685)
1. Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform.
Udayakumar D; Zhang Z; Xi Y; Dwivedi DK; Fulkerson M; Haldeman S; McKenzie T; Yousuf Q; Joyce A; Hajibeigi A; Notgrass H; de Leon AD; Yuan Q; Lewis MA; Madhuranthakam AJ; Sibley RC; Elias R; Guo J; Christie A; McKay RM; Cadeddu JA; Bagrodia A; Margulis V; Brugarolas J; Wang T; Kapur P; Pedrosa I
Clin Cancer Res; 2021 Sep; 27(17):4794-4806. PubMed ID: 34210685
[TBL] [Abstract][Full Text] [Related]
2. Comparative diagnostic performance of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for differentiating clear cell and non-clear cell renal cell carcinoma.
Zhao P; Zhu J; Wang L; Li N; Zhang X; Li J; Luo Y; Li Q
Eur Radiol; 2023 May; 33(5):3766-3774. PubMed ID: 36725722
[TBL] [Abstract][Full Text] [Related]
3. Statistical clustering of parametric maps from dynamic contrast enhanced MRI and an associated decision tree model for non-invasive tumour grading of T1b solid clear cell renal cell carcinoma.
Xi Y; Yuan Q; Zhang Y; Madhuranthakam AJ; Fulkerson M; Margulis V; Brugarolas J; Kapur P; Cadeddu JA; Pedrosa I
Eur Radiol; 2018 Jan; 28(1):124-132. PubMed ID: 28681074
[TBL] [Abstract][Full Text] [Related]
4. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
Halefoglu AM; Ozagari AA
Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
[TBL] [Abstract][Full Text] [Related]
5. Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study.
Yin Q; Hung SC; Wang L; Lin W; Fielding JR; Rathmell WK; Khandani AH; Woods ME; Milowsky MI; Brooks SA; Wallen EM; Shen D
Sci Rep; 2017 Mar; 7():43356. PubMed ID: 28256615
[TBL] [Abstract][Full Text] [Related]
6. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.
Cai Q; Christie A; Rajaram S; Zhou Q; Araj E; Chintalapati S; Cadeddu J; Margulis V; Pedrosa I; Rakheja D; McKay RM; Brugarolas J; Kapur P
EBioMedicine; 2020 Jan; 51():102526. PubMed ID: 31859241
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
Rosen MA; Schnall MD
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Flaherty KT; Rosen MA; Heitjan DF; Gallagher ML; Schwartz B; Schnall MD; O'Dwyer PJ
Cancer Biol Ther; 2008 Apr; 7(4):496-501. PubMed ID: 18219225
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging as a biomarker in renal cell carcinoma.
Pedrosa I; Alsop DC; Rofsky NM
Cancer; 2009 May; 115(10 Suppl):2334-45. PubMed ID: 19402070
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis on magnetic resonance imaging correlates with aggressive histology and disease progression in clear cell renal cell carcinoma.
Beddy P; Genega EM; Ngo L; Hindman N; Wei J; Bullock A; Bhatt RS; Atkins MB; Pedrosa I
Clin Genitourin Cancer; 2014 Feb; 12(1):55-62. PubMed ID: 24145001
[TBL] [Abstract][Full Text] [Related]
11. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT.
Brufau BP; Cerqueda CS; Villalba LB; Izquierdo RS; González BM; Molina CN
Radiographics; 2013 Oct; 33(6):1691-716. PubMed ID: 24108558
[TBL] [Abstract][Full Text] [Related]
12. Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity.
Yuan Q; Kapur P; Zhang Y; Xi Y; Carvo I; Signoretti S; Dimitrov IE; Cadeddu JA; Margulis V; Brugarolas J; Madhuranthakam AJ; Pedrosa I
Clin Genitourin Cancer; 2016 Dec; 14(6):e585-e594. PubMed ID: 27209349
[TBL] [Abstract][Full Text] [Related]
13. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA
AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750
[TBL] [Abstract][Full Text] [Related]
14. The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
Hudson JM; Bailey C; Atri M; Stanisz G; Milot L; Williams R; Kiss A; Burns PN; Bjarnason GA
Eur Radiol; 2018 Jun; 28(6):2281-2290. PubMed ID: 29383520
[TBL] [Abstract][Full Text] [Related]
15. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma.
Zeng H; Chen L; Wang M; Luo Y; Huang Y; Ma X
Aging (Albany NY); 2021 Mar; 13(7):9960-9975. PubMed ID: 33795526
[TBL] [Abstract][Full Text] [Related]
16. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.
Golkaram M; Kuo F; Gupta S; Carlo MI; Salmans ML; Vijayaraghavan R; Tang C; Makarov V; Rappold P; Blum KA; Zhao C; Mehio R; Zhang S; Godsey J; Pawlowski T; DiNatale RG; Morris LGT; Durack J; Russo P; Kotecha RR; Coleman J; Chen YB; Reuter VE; Motzer RJ; Voss MH; Liu L; Reznik E; Chan TA; Hakimi AA
Genome Med; 2022 Dec; 14(1):143. PubMed ID: 36536472
[TBL] [Abstract][Full Text] [Related]
17. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
18. Deep learning and radiomics: the utility of Google TensorFlow™ Inception in classifying clear cell renal cell carcinoma and oncocytoma on multiphasic CT.
Coy H; Hsieh K; Wu W; Nagarajan MB; Young JR; Douek ML; Brown MS; Scalzo F; Raman SS
Abdom Radiol (NY); 2019 Jun; 44(6):2009-2020. PubMed ID: 30778739
[TBL] [Abstract][Full Text] [Related]
19. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
[TBL] [Abstract][Full Text] [Related]
20. Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
Beuselinck B; Pans S; Bielen J; De Wever L; Noppe N; Vanderschueren G; De Keyzer F; Baldewijns M; Lerut E; Laenen A; Verbiest A; Roussel E; Albersen M; Vandecaveye V
Acta Oncol; 2020 Jul; 59(7):818-824. PubMed ID: 32297532
[No Abstract] [Full Text] [Related]
[Next] [New Search]
